177 related articles for article (PubMed ID: 37368929)
1. Predictive Value of Serum Biomarkers for Response of Limited-Stage AIDS-Associated Kaposi Sarcoma to Antiretroviral Therapy With or Without Concomitant Chemotherapy in Resource-Limited Settings.
Epeldegui M; Chang D; Lee J; Magpantay LI; Borok M; Bukuru A; Busakhala N; Godfrey C; Hosseinipour MC; Kang M; Kanyama C; Langat D; Mngqibisa R; Mwelase N; Nyirenda M; Samaneka W; Hoagland B; Campbell TB; Martínez-Maza O; Krown SE;
J Acquir Immune Defic Syndr; 2023 Oct; 94(2):165-173. PubMed ID: 37368929
[TBL] [Abstract][Full Text] [Related]
2. As-Needed Vs Immediate Etoposide Chemotherapy in Combination With Antiretroviral Therapy for Mild-to-Moderate AIDS-Associated Kaposi Sarcoma in Resource-Limited Settings: A5264/AMC-067 Randomized Clinical Trial.
Hosseinipour MC; Kang M; Krown SE; Bukuru A; Umbleja T; Martin JN; Orem J; Godfrey C; Hoagland B; Mwelase N; Langat D; Nyirenda M; MacRae J; Borok M; Samaneka W; Moses A; Mngqbisa R; Busakhala N; Martínez-Maza O; Ambinder R; Dittmer DP; Nokta M; Campbell TB;
Clin Infect Dis; 2018 Jul; 67(2):251-260. PubMed ID: 29365083
[TBL] [Abstract][Full Text] [Related]
3. Early Progression and Immune Reconstitution Inflammatory Syndrome During Treatment of Mild-To-Moderate Kaposi Sarcoma in Sub-Saharan Africa and South America: Incidence, Long-Term Outcomes, and Effects of Early Chemotherapy.
Nyirenda M; Ngongondo M; Kang M; Umbleja T; Krown SE; Godfrey C; Samaneka W; Mngqibisa R; Hoagland B; Mwelase N; Caruso S; Martinez-Maza O; Dittmer DP; Borok M; Hosseinipour MC; Campbell TB;
J Acquir Immune Defic Syndr; 2020 Aug; 84(4):422-429. PubMed ID: 32265361
[TBL] [Abstract][Full Text] [Related]
4. Paclitaxel for anthracycline-resistant AIDS-related Kaposi's sarcoma: clinical and angiogenic correlations.
Stebbing J; Wildfire A; Portsmouth S; Powles T; Thirlwell C; Hewitt P; Nelson M; Patterson S; Mandalia S; Gotch F; Gazzard BG; Bower M
Ann Oncol; 2003 Nov; 14(11):1660-6. PubMed ID: 14581275
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of plasma human herpesvirus 8 DNA as a marker of clinical outcomes during antiretroviral therapy for AIDS-related Kaposi sarcoma in Zimbabwe.
Borok M; Fiorillo S; Gudza I; Putnam B; Ndemera B; White IE; Gwanzura L; Schooley RT; Campbell TB
Clin Infect Dis; 2010 Aug; 51(3):342-9. PubMed ID: 20572760
[TBL] [Abstract][Full Text] [Related]
6. Rapamycin with antiretroviral therapy in AIDS-associated Kaposi sarcoma: an AIDS Malignancy Consortium study.
Krown SE; Roy D; Lee JY; Dezube BJ; Reid EG; Venkataramanan R; Han K; Cesarman E; Dittmer DP
J Acquir Immune Defic Syndr; 2012 Apr; 59(5):447-54. PubMed ID: 22067664
[TBL] [Abstract][Full Text] [Related]
7. Therapy of special HIV-associated diseases: HCV-HIV-co-infection and AIDS-related Kaposi's sarcoma - official satellite to the 7th European Conference on Clinical Aspects and Treatment of HIV-infection, October 23, 1999 in Lisbon, Portugal.
Goebel FD; Jablonowski H
Eur J Med Res; 1999 Dec; 4(12):507-13. PubMed ID: 10611054
[TBL] [Abstract][Full Text] [Related]
8. Treatment of advanced AIDS-associated Kaposi sarcoma in resource-limited settings: a three-arm, open-label, randomised, non-inferiority trial.
Krown SE; Moser CB; MacPhail P; Matining RM; Godfrey C; Caruso SR; Hosseinipour MC; Samaneka W; Nyirenda M; Busakhala NW; Okuku FM; Kosgei J; Hoagland B; Mwelase N; Oliver VO; Burger H; Mngqibisa R; Nokta M; Campbell TB; Borok MZ;
Lancet; 2020 Apr; 395(10231):1195-1207. PubMed ID: 32145827
[TBL] [Abstract][Full Text] [Related]
9. Soluble biomarkers of HIV-1-related systemic immune activation are associated with high plasma levels of growth factors implicated in the pathogenesis of Kaposi sarcoma in adults.
Nana BC; Esemu LF; Besong ME; Atchombat DHN; Ogai K; Sobgui TMP; Nana CMM; Seumko'o RMN; Awanakan H; Ekali GL; Leke RGF; Okamoto S; Ndhlovu LC; Megnekou R
Front Immunol; 2023; 14():1216480. PubMed ID: 37809059
[TBL] [Abstract][Full Text] [Related]
10. Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma: higher incidence and mortality in Africa than in the UK.
Letang E; Lewis JJ; Bower M; Mosam A; Borok M; Campbell TB; Naniche D; Newsom-Davis T; Shaik F; Fiorillo S; Miro JM; Schellenberg D; Easterbrook PJ
AIDS; 2013 Jun; 27(10):1603-13. PubMed ID: 23462220
[TBL] [Abstract][Full Text] [Related]
11. Comparison of constitutive cytokine release in high and low histologic grade AIDS-related Kaposi's sarcoma cell strains and in sera from HIV+/KS+ and HIV+/KS- patients.
Bailer RT; Lazo A; Ng-Bautista CL; Hout BL; Ness GM; Hegtvedt AK; Blakeslee JR; Stephens RE; Brierley GP; Mallery SR
J Interferon Cytokine Res; 1995 May; 15(5):473-83. PubMed ID: 7648450
[TBL] [Abstract][Full Text] [Related]
12. AIDS-associated Kaposi sarcoma: outcomes after initiation of antiretroviral therapy at a university-affiliated hospital in urban Zimbabwe.
Nelson BC; Borok MZ; Mhlanga TO; Makadzange AT; Campbell TB
Int J Infect Dis; 2013 Oct; 17(10):e902-6. PubMed ID: 23809198
[TBL] [Abstract][Full Text] [Related]
13. Plasma biomarkers of clinical response during chemotherapy plus combination antiretroviral therapy (cART) in HIV+ patients with advanced Kaposi sarcoma.
Tedeschi R; Bidoli E; Bortolin MT; Schioppa O; Vaccher E; De Paoli P
Oncotarget; 2015 Oct; 6(30):30334-42. PubMed ID: 26296972
[TBL] [Abstract][Full Text] [Related]
14. Treatment and outcome of AIDS-related Kaposi sarcoma in South Africa, Malawi and Zambia: an international comparison.
Rohner E; Kasaro M; Msadabwe-Chikuni SC; Stinson K; Mohamed Z; Tweya H; Egger M; Bohlius J
Pan Afr Med J; 2017; 28():261. PubMed ID: 29881504
[TBL] [Abstract][Full Text] [Related]
15. Fractionated doses of oral etoposide in the treatment of patients with aids-related kaposi sarcoma: a clinical and pharmacologic study to improve therapeutic index.
Sprinz E; Caldas AP; Mans DR; Cancela A; DiLeone L; Dalla Costa T; Schwartsmann G
Am J Clin Oncol; 2001 Apr; 24(2):177-84. PubMed ID: 11319295
[TBL] [Abstract][Full Text] [Related]
16. Management of Kaposi's sarcoma in resource-limited settings in the era of HAART.
Lynen L; Zolfo M; Huyst V; Louis F; Barnardt P; Van de Velde A; De Schacht C; Colebunders R
AIDS Rev; 2005; 7(1):13-21. PubMed ID: 15875657
[TBL] [Abstract][Full Text] [Related]
17. Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death.
Boulware DR; Hullsiek KH; Puronen CE; Rupert A; Baker JV; French MA; Bohjanen PR; Novak RM; Neaton JD; Sereti I;
J Infect Dis; 2011 Jun; 203(11):1637-46. PubMed ID: 21592994
[TBL] [Abstract][Full Text] [Related]
18. Adriamycin, bleomycin and vincristine chemotherapy with recombinant granulocyte-macrophage colony-stimulating factor in the treatment of AIDS-related Kaposi's sarcoma.
Gill PS; Bernstein-Singer M; Espina BM; Rarick M; Magy F; Montgomery T; Berry MS; Levine A
AIDS; 1992 Dec; 6(12):1477-81. PubMed ID: 1283520
[TBL] [Abstract][Full Text] [Related]
19. Clinical features and serum biomarkers in HIV immune reconstitution inflammatory syndrome after cryptococcal meningitis: a prospective cohort study.
Boulware DR; Meya DB; Bergemann TL; Wiesner DL; Rhein J; Musubire A; Lee SJ; Kambugu A; Janoff EN; Bohjanen PR
PLoS Med; 2010 Dec; 7(12):e1000384. PubMed ID: 21253011
[TBL] [Abstract][Full Text] [Related]
20. The soluble form of the IL-6 receptor (sIL-6R alpha) is a potent growth factor for AIDS-associated Kaposi's sarcoma (KS) cells; the soluble form of gp130 is antagonistic for sIL-6R alpha-induced AIDS-KS cell growth.
Murakami-Mori K; Taga T; Kishimoto T; Nakamura S
Int Immunol; 1996 Apr; 8(4):595-602. PubMed ID: 8722639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
